



EPF-Medicines for Europe dialogue 2018

Date: Monday 08 October 2018

Time: 12:30 -17:00

Venue: Thon EU Hotel, Brussels, Belgium

Building on increased collaboration and ongoing initiatives over the last several years, the European Patients' Forum and Medicines for Europe are delighted to invite you to the third annual structured dialogue between members.

The objective of this meeting is to gather the views of patients and of the generic, biosimilar and value added medicines sectors on how to optimise efforts for better access to high quality medicines for patients.

Agenda

Each session is expected to last around 40 mins. Each session should include 10 minutes at the end to discuss ways forward and potential areas of collaboration

12.30-13.30 Lunch

13.30 Introduction and welcome to the event: Nicola Bedlington and Adrian van den Hoven

13.45 - 14.25 Session 1- EPF's Roadmap to achieving universal health coverage for all by 2030

Background

EPF published a Roadmap to achieving universal health coverage for all by 2030 in December 2017 as a result of its 2017 campaign on Access to Healthcare. Relevant parts of the Roadmap will be presented. A discussion will follow to identify which actions Medicines for Europe and their members can contribute to implementing. The Roadmap calls on MS and EU policymakers to implement



recommended actions, but it also calls on relevant stakeholders to take responsibility for actions that they can implement and make progress on.

14.25 - 15.05 Session 2 – Generic medicines: Ensuring patient access to essential medicines

Background

The generic medicines industry provides essential medicines that European patients, healthcare professionals and healthcare systems rely on to treat most acute and chronic ailments ranging from cardiovascular, to diabetes, HIV/AIDS and even to cancer. Generic medicines have significantly increased access to medicines for patients in an era of rising demands for healthcare services and constrained finances. Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas without increasing the overall treatment cost.

15.05-15.20 Coffee break

15.20-16.00 Session 3 – Biosimilar medicines – Increasing patient access to biological medicines

Background

Biosimilar medicines were invented in Europe 20 years ago to address the pressing need for better access to biological medicines in Europe. Due to the high cost of many biological medicines in Europe, we have seen an inequity in access to treatment because lower income countries in Europe cannot afford such therapies. Biosimilar medicines provide the opportunity to increase patient access to the medicines they need to manage conditions such as diabetes, cancer, arthritis, and psoriasis.

16.00-16.40 Session 4 – Value added medicines and Patient Involvement – Improving patient quality of life through tailored medicines

Background

Value Added Medicines contribute to addressing unmet patient needs. Moving from a one-size-fits-all to a more tailored and patient-specific approach, value added medicines are one of the key components of the customisation of healthcare. By answering patients' unmet needs, they represent a new horizon for those who are currently looking forward to a better quality of life with their treatment. The benefits of value added medicines include convenient delivery models for patients, increased therapeutic adherence, and medicine combinations.

16.40 Wrap up and close: Nicola Bedlington and Adrian van den Hoven